Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting
Portfolio Pulse from
Eli Lilly's Phase 3 trial results for Jaypirca® (pirtobrutinib) show a significant reduction in disease progression risk for chronic lymphocytic leukemia patients previously treated with BTK inhibitors. The study demonstrated a 46% reduction in risk compared to other treatments, with a median time to next treatment or death of 23.9 months.
December 09, 2024 | 11:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's Jaypirca® (pirtobrutinib) demonstrated a 46% reduction in disease progression risk in CLL patients previously treated with BTK inhibitors, meeting the primary endpoint of progression-free survival in the Phase 3 BRUIN CLL-321 trial.
The positive Phase 3 trial results for Jaypirca® indicate a significant advancement in treatment for CLL, likely boosting investor confidence and potentially increasing Eli Lilly's stock price. The achievement of the primary endpoint and the substantial reduction in disease progression risk are critical factors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100